InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announced today the closing of a €20 million round of equity financing. Founded in 2015 by Giovanni Righini, a 30-year veteran of the heart valve industry, the company maintains offices outside Milan, Italy, and Boston, Massachusetts.


InnovHeart s.r.l, with locations in Milan, Italy, and Newton, Mass., USA, develops Transcatheter Mitral Valve Replacement systems (TMVR) to treat patients suffering from mitral valve disease. The company is conducting clinical trials of its novel Saturn TMVR system. Saturn is a low-profile mitral heart valve designed for trans-apical or trans-septal delivery.

Transcatheter Mitral Valve Replacement Company InnovHeart Closes Series B Financing of €20 Million

Description

Company Information

Funding Insights

Transcatheter Mitral Valve Replacement Company InnovHeart Closes Series B Financing of €20 Million

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information